Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 402 results for "warner chilcott"

Former Warner Chilcott CFO Paul Herendeen takes that spot at Z...

Paul Herendeen has been appointed as the new executive vice president and chief financial officer ofZoetis ( $ZTS ), the animal health industry leader. Reporting to CEO Juan Ramón Alaix, he will oversee the company's finance and IT segments. He ... FiercePharma, 1 month ago
New finance chief at Zoetis Seeking Alpha, 1 month ago
Zoetis appoints executive vice president and CFO, 3 weeks ago

1 images for "warner chilcott"

BDlive, 1 month ago

Warner Chilcott Shares Up 69.5% Since SmarTrend's Buy Recommendation (WCRX)

Written on Thu, 08/07/2014 - 6:18pm By Shiri Gupta SmarTrend identified an Uptrend for Warner Chilcott ( NASDAQ:WCRX ) on January 17th, 2013 at $13.53. In approximately 19 months, Warner Chilcott has returned 69.54% as of today's recent price ...
 Comtex SmarTrend1 month ago

Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog

Results were boosted by the inclusion of products from the Warner Chilcott acquisition. Quarterly Details Actavis has two revenue producing segments -- Actavis Pharma and Anda Distribution. While Actavis Pharma includes all branded, branded ...
 Nasdaq1 month ago

Warner Chilcott, Mayne Pharma to Settle Over Claims on Generic Doryx Delay

Brand manufacturer Mayne Pharma and the U.S. marketer of Mayne's acne drug Doryx, Warner Chilcott, have moved to settle class action claims with third party purchasers that allege the two companies inappropriately delayed generic competition on the ...
 FDA News1 month ago

Loestrin 24 Generic Pay-for-Delay Suit Tossed Out

A federal judge has tossed out all claims in a consolidated class-action antitrust lawsuit alleging that brandmaker Warner Chilcott executed a reverse payment to generics firms Watson (now Actavis) and Lupin Pharmaceuticals to delay generic ...
 FDA News1 week ago
Pharma Letter

Actavis Enters New Markets To Boost Profits, Sales

Generic-drugmaker Actavis (NYSE: ACT ) has moved its headquarters to Ireland and is trying to develop its own branded drugs to cut costs and boost revenue. The company, formerly known as Watson Pharmaceuticals, boasts five straight quarters of ...
 Investor's Business Daily5 hours ago Actavis reports 2nd-qtr revenues increase by over a third  Pharma Letter1 month ago Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42  Benzinga.com1 month ago

Can Washington Get Its Act Together to Stop Tax Inversions?

At the Morgan Stanley Global Healthcare Conference on September 9, Merck CEO Ken Frazier told investors he wouldn't join the giant wave of companies pursuing overseas acquisitions so they can move abroad and escape high U.S. corporate taxes. Such ...
 The Fiscal Times9 hours ago Capital Flight: Can Tax Inversions Be Prevented?  Wharton3 days ago Merck's Frazier disses tax inversion strategy, at least for Merck  FiercePharma1 week ago

Benzinga's Weekend M&A Chatter

The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday September 12 through Sunday September 14, 2014: Google Rumored to be Taking Up to 40% Stake in Ebay The Rumor: Shares of Ebay, Inc. (NASDAQ: EBAY) surged ...
 Benzinga.com5 days ago
Bidness Etc

Bank of America Loses Top Deal Banker To Barclays

Bank of America has lost one of its top deal bankers to Barclays as the British bank looks to continue its success in the M&A advisory business Page 1 of 2 Published: September 10, 2014 at 4:22 pm EST By: Troy Kuhn Click Ticker to See live ...
 Bidness Etc1 week ago Barclays Appoints Top BofA Banker To Head Its M&A Structuring : FT  RTTNews.com1 week ago

Another district court holds that reverse payment means cash under FTC v. Actavis

On Thursday, September 4, the US District Court in Rhode Island held that FTC v. Actavis, 133 S. Ct. 2223 (2013) requires a monetary payment from the patent owner to the potential generic challenger to support a so-called reverse payment claim, ...
 Lexology1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less